Current perspectives and the future of disease-modifying therapies in type 1 diabetes  

作　　者：Sunetra Mondal Joseph M Pappachan 

机构地区：[1]Department of Endocrinology,NRS Medical College and Hospital,Kolkata 700014,West Bengal,India [2]Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [3]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [4]Department of Endocrinology,Kasturba Medical College,Manipal 576104,India

出　　处：《World Journal of Diabetes》2025年第1期12-21,共10页世界糖尿病杂志（英文）

摘　　要：Use of immunomodulating agents to prevent the progression of autoimmuneβ-cell damage leading to type 1 diabetes mellitus(T1DM)is an interesting area for research.These include non-specific anti-inflammatory agents,immunologic vaccination and anti-inflammatory agents targeting specific immune cells or cytokines.Teplizumab is an anti-CD3-molecule that binds to and leads to the disappearance of the CD3/TCR complex and rendering the T cell anergic to its target antigen.Preclinical and clinical trials have demonstrated its efficacy in reducing the decline in serum C-peptide levels and the need for insulin therapy if used early in the disease process of T1DM.The benefits have been apparent as early as six months to as long as seven years after therapy.It has recently been approved by the Food and Drug Administration to delay the onset of clinical(stage 3)type 1 diabetes in children above 8 years of age.In their recent metaanalysis published in the World Journal of Diabetes,Ma et al found that those in the teplizumab treatment group have a greater likelihood of reduction in insulin use,change in C-peptide response,and better glycemic control compared to the control group with a good safety profile.However,all the included randomized control trials have been conducted in high-income countries.High cost of therapy and unknown utility of the molecule in stage 3 disease limit its widespread use.

关 键 词：Teplizumab Type 1 diabetes mellitus Disease modifying therapy β-cell function C-PEPTIDE IMMUNOTHERAPY 

分 类 号：R587.1[医药卫生—内分泌]